Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1999 1
2000 2
2001 1
2003 1
2004 2
2005 3
2006 3
2007 5
2008 2
2009 1
2010 4
2011 3
2012 8
2013 5
2014 5
2015 6
2016 4
2017 5
2018 6
2019 5
2020 3
2021 6
2022 3
2023 3
2024 3
2025 6
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.
Vinogradova Y, Coupland C, Hippisley-Cox J. Vinogradova Y, et al. BMJ. 2019 Jan 9;364:k4810. doi: 10.1136/bmj.k4810. BMJ. 2019. PMID: 30626577 Free PMC article.
OBJECTIVE: To assess the association between risk of venous thromboembolism and use of different types of hormone replacement therapy. DESIGN: Two nested case-control studies. ...CONCLUSIONS: In the present study, transdermal treatment was the safest type of …
OBJECTIVE: To assess the association between risk of venous thromboembolism and use of different types of hormone replacement …
Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery.
Shufelt CL, Manson JE. Shufelt CL, et al. J Clin Endocrinol Metab. 2021 Apr 23;106(5):1245-1254. doi: 10.1210/clinem/dgab042. J Clin Endocrinol Metab. 2021. PMID: 33506261 Free PMC article. Review.
METHODS: This summary is based on authors' knowledge in the field of menopausal HT and supplemented by a PubMed search using the terms "menopause hormone therapy," "transdermal," "estradiol," "conjugated estrogens," "bioidentical," "cardiovascular disease," "lipopro …
METHODS: This summary is based on authors' knowledge in the field of menopausal HT and supplemented by a PubMed search using the terms "meno …
The use of HRT containing transdermal estradiol in women with a personal history of venous or arterial thromboembolism: A consecutive series of 115 cases.
Howells P, Hussain S, Hulme E, Vigneswaran K, Zia S, Hassan M, Arya R, Hamoda H. Howells P, et al. Post Reprod Health. 2025 Dec;31(4):249-253. doi: 10.1177/20533691251369205. Epub 2025 Aug 22. Post Reprod Health. 2025. PMID: 40842373 Free PMC article.
ObjectiveTo assess the risk of further thrombosis with using HRT containing transdermal estradiol in women with a personal history of venous thromboembolism (VTE) or arterial thromboembolism (ATE).MethodsWe undertook analysis of patients with a …
ObjectiveTo assess the risk of further thrombosis with using HRT containing transdermal estradiol in women with a personal his …
PCOS and Obesity: Contraception Challenges.
Meczekalski B, Rasi M, Battipaglia C, Fidecicchi T, Bala G, Szeliga A, Luisi S, Genazzani AD. Meczekalski B, et al. Open Access J Contracept. 2025 May 5;16:43-58. doi: 10.2147/OAJC.S501434. eCollection 2025. Open Access J Contracept. 2025. PMID: 40352401 Free PMC article. Review.
It seems that there is no clinical advantage in using high-dose ethinyl estradiol over low-dose formulations. Lower-dose EE formulations may be considered a safer option for obese PCOS patients. ...Progestin-only (POPs) formulations have minimal metabolic effects, making t …
It seems that there is no clinical advantage in using high-dose ethinyl estradiol over low-dose formulations. Lower-dose EE formulati …
The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review.
Oliver-Williams C, Glisic M, Shahzad S, Brown E, Pellegrino Baena C, Chadni M, Chowdhury R, Franco OH, Muka T. Oliver-Williams C, et al. Hum Reprod Update. 2019 Mar 1;25(2):257-271. doi: 10.1093/humupd/dmy039. Hum Reprod Update. 2019. PMID: 30508190 Free article.
In women with increased baseline thromboembolic risk, alternative non-hormonal medications are suggested as first-line treatment and transdermal estradiol alone or with micronized progesterone only should be considered when these options are not effective. When HT i …
In women with increased baseline thromboembolic risk, alternative non-hormonal medications are suggested as first-line treatment and tran …
Menopausal Hormone Therapy-Risks, Benefits and Emerging Options: A Narrative Review.
Arnautu AM, Nimigean VR, Nacea-Radu CA, Tilici DM, Paun DL. Arnautu AM, et al. Int J Mol Sci. 2025 Nov 17;26(22):11098. doi: 10.3390/ijms262211098. Int J Mol Sci. 2025. PMID: 41303580 Free PMC article. Review.
Initiation within 10 years of menopause as well as the use of transdermal estradiol at low-moderate doses are favored when cardiometabolic or thrombotic risk is salient. In contrast, oral regimens-particularly those using conjugated equine estrogens-are associated w …
Initiation within 10 years of menopause as well as the use of transdermal estradiol at low-moderate doses are favored when car …
Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis.
Scarabin PY. Scarabin PY. Climacteric. 2018 Aug;21(4):341-345. doi: 10.1080/13697137.2018.1446931. Epub 2018 Mar 23. Climacteric. 2018. PMID: 29570359 Review.
Postmenopausal hormone therapy (HT) is a modifiable risk factor for venous thromboembolism (VTE). While the route of estrogen administration is now well recognized as an important determinant of VTE risk, there is also increasing evidence that progestogens ma …
Postmenopausal hormone therapy (HT) is a modifiable risk factor for venous thromboembolism (VTE). While the route of estrogen …
Venous thromboembolism in the hormonal milieu.
Connell NT, Connors JM. Connell NT, et al. Curr Opin Hematol. 2020 Sep;27(5):327-332. doi: 10.1097/MOH.0000000000000599. Curr Opin Hematol. 2020. PMID: 32740039 Review.
Data suggest varying degrees of increased risk for venous thromboembolism (VTE). RECENT FINDINGS: While oral progestin only methods do not appear to increase the risk of VTE, an association was seen with injection progestin contraception. ...While transdermal …
Data suggest varying degrees of increased risk for venous thromboembolism (VTE). RECENT FINDINGS: While oral progestin only me …
Transdermal estradiol for the management of refractory uremic bleeding.
Gonzalez J, Bryant S, Hermes-DeSantis ER. Gonzalez J, et al. Am J Health Syst Pharm. 2018 May 1;75(9):e177-e183. doi: 10.2146/ajhp170241. Am J Health Syst Pharm. 2018. PMID: 29691259 Review.
PURPOSE: The efficacy and thrombogenicity of transdermal estradiol in the management of refractory uremic bleeding in adults are examined. ...The management of uremic bleeding will require long-term therapy, and case reports have documented the safe use of transd …
PURPOSE: The efficacy and thrombogenicity of transdermal estradiol in the management of refractory uremic bleeding in adults a …
92 results